ATE336263T1 - Stabile gelzusammensetzung zur topischen behandlung von hautkrankheiten - Google Patents

Stabile gelzusammensetzung zur topischen behandlung von hautkrankheiten

Info

Publication number
ATE336263T1
ATE336263T1 AT01202699T AT01202699T ATE336263T1 AT E336263 T1 ATE336263 T1 AT E336263T1 AT 01202699 T AT01202699 T AT 01202699T AT 01202699 T AT01202699 T AT 01202699T AT E336263 T1 ATE336263 T1 AT E336263T1
Authority
AT
Austria
Prior art keywords
stable gel
gel
topical treatment
gel composition
skin diseases
Prior art date
Application number
AT01202699T
Other languages
English (en)
Inventor
Prakash M Charu
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE336263T1 publication Critical patent/ATE336263T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01202699T 1994-06-07 1995-06-07 Stabile gelzusammensetzung zur topischen behandlung von hautkrankheiten ATE336263T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25509494A 1994-06-07 1994-06-07

Publications (1)

Publication Number Publication Date
ATE336263T1 true ATE336263T1 (de) 2006-09-15

Family

ID=22966815

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95923779T ATE215836T1 (de) 1994-06-07 1995-06-07 Stabilgelzusammensetzung zur topischen behandlung von hautkrankheiten
AT01202699T ATE336263T1 (de) 1994-06-07 1995-06-07 Stabile gelzusammensetzung zur topischen behandlung von hautkrankheiten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT95923779T ATE215836T1 (de) 1994-06-07 1995-06-07 Stabilgelzusammensetzung zur topischen behandlung von hautkrankheiten

Country Status (13)

Country Link
US (2) US5914334A (de)
EP (2) EP0764032B1 (de)
AT (2) ATE215836T1 (de)
AU (1) AU693905B2 (de)
CA (1) CA2191773C (de)
DE (2) DE69526344T2 (de)
DK (1) DK1147778T3 (de)
ES (2) ES2173958T3 (de)
IL (3) IL122358A (de)
PT (1) PT1147778E (de)
TW (1) TW379143B (de)
WO (1) WO1995033489A1 (de)
ZA (1) ZA954599B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
IT1288708B1 (it) * 1996-10-17 1998-09-23 Achille Sandoli Composizione farmaceutica comprendente trometamina per il trattamento per via topica dell'acne vulgaris.
EP0969847A1 (de) * 1997-02-20 2000-01-12 Allergan Sales, Inc. Tazarotene und carticosteroid enthaltende zusammensetzungen zur behandlung von psoriasis
WO1998056375A1 (en) * 1997-06-11 1998-12-17 Allergan Sales, Inc. Tazarotene and uvb phototherapy treatment for psoriasis
WO1999049841A1 (en) * 1998-03-30 1999-10-07 The Procter & Gamble Company Skin care compositions
US20020160995A1 (en) * 1998-08-03 2002-10-31 Easterling W. Jerry Medication and method for remediating existing scars through transdermal, topical delivery of calcium channel blockers
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
CN1438861A (zh) * 2000-04-26 2003-08-27 沃特森药物公司 最小化与奥昔布宁疗法有关的副作用
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
FR2830449B1 (fr) * 2001-10-05 2004-04-23 Fabre Pierre Dermo Cosmetique Utilisation du tazarotene pour la preparation d'un vernis a ongles pour le traitement et/ou la prevention du psoriasis et un vernis a ongles le contenant
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
TR201815573T4 (tr) * 2002-05-28 2018-11-21 Astrazeneca Ab Topikal olarak uygulanabilir farmasötik preparasyon.
US20040018220A1 (en) * 2002-07-26 2004-01-29 Chiou Consulting, Inc. Aqueous compositions for facial cosmetics
FR2848451B1 (fr) * 2002-12-17 2007-01-12 Galderma Res & Dev Procede de stabilisation chimique d'un retinoide solubilise et composition aqueuse obtenue selon le procede comprenant au moins un retinoide sous forme salifiee
AU2003296758A1 (en) * 2002-12-17 2004-07-09 Galderma Research & Development, S.N.C. Process for the chemical stabilization of a solubilized retinoid in a solvent using a base
AU2006245283B2 (en) 2005-05-10 2012-11-01 Dermipsor Ltd. Compositions and methods for treating hyperproliferative epidermal diseases
AR054805A1 (es) * 2005-06-29 2007-07-18 Stiefel Laboratories Composiciones topicas para el tratamiento de la piel
US20070060620A1 (en) * 2005-09-09 2007-03-15 John Sefton Use of RAR retinoid agonists to increase sperm count and sperm mobility in males
JP2009510087A (ja) * 2005-09-30 2009-03-12 オーエムピー インコーポレーテッド 安定アスコルビン酸組成物
US20070269534A1 (en) * 2006-02-02 2007-11-22 Ramirez Jose E Methods of treating skin to enhance therapeutic treatment thereof
US20070178058A1 (en) * 2006-02-02 2007-08-02 Ramirez Jose E Methods of using stable ascorbic acid compositions
US9107844B2 (en) * 2006-02-03 2015-08-18 Stiefel Laboratories Inc. Topical skin treating compositions
BRPI0709674A2 (pt) 2006-03-31 2011-12-06 Stiefel Research Australia Pty Ltd. gel de suspensão espumante
MXPA06008988A (es) * 2006-08-08 2008-02-07 Fernando Ahumada Ayala Preparaciones topicas antiacne que contienen retinoide (tazaroteno o adapaleno), antibiotico (fosfato de clindamicina) y/o queratolitico (peroxido de bonzoilo en microesponjas).
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US20110117182A1 (en) * 2009-07-30 2011-05-19 Allergan, Inc. Combination of dapsone with other anti-acne agents
HUE033144T2 (en) 2010-03-12 2017-11-28 Monsanto Technology Llc Agrochemical gel preparations
JP2013538868A (ja) * 2010-10-08 2013-10-17 ヘルパービー セラピューティクス リミテッド 新規な組成物
WO2015063723A1 (en) 2013-10-31 2015-05-07 Ranbaxy Laboratories Limited Topical pharmaceutical composition of acitretin
US11311529B2 (en) * 2018-11-08 2022-04-26 Varsona Therapeutics, Inc. Topical formulations of 5-α-reductase inhibitors and uses thereof
US11311556B2 (en) 2020-05-13 2022-04-26 Varsona Therapeutics, Inc. Topical dutasteride emulsions for treating endocrine therapy-induced alopecia
KR20230039979A (ko) * 2021-09-15 2023-03-22 서울대학교산학협력단 아토피 피부염 예방 또는 치료용 겔 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3934028A (en) * 1974-04-22 1976-01-20 The Regents Of The University Of California Acne and psoriasis treatment with retinoic acid analogs
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US4810804A (en) * 1987-03-26 1989-03-07 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid-like activity
EP0481007B1 (de) * 1989-06-07 1997-01-22 BAZZANO, Gail S VEHIKEL MIT LANGSAMER FREISETZUNG ZUR VERMINDERUNG DER HAUTREIZUNG TOPISCHER retinoidhaltiger MITTEL
AU670777B2 (en) * 1992-04-16 1996-08-01 Ortho Pharmaceutical Corporation Aqueous gel vehicles for retinoids
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
WO1998056375A1 (en) * 1997-06-11 1998-12-17 Allergan Sales, Inc. Tazarotene and uvb phototherapy treatment for psoriasis
US6017938A (en) * 1998-07-28 2000-01-25 Bershad; Susan Short contact treatment for acne
US6114348A (en) * 1999-03-10 2000-09-05 Weber; Paul J. Method of treating warts using tazarotene

Also Published As

Publication number Publication date
IL122359A (en) 2001-08-26
AU693905B2 (en) 1998-07-09
ATE215836T1 (de) 2002-04-15
DE69526344D1 (de) 2002-05-16
EP1147778B1 (de) 2006-08-16
ZA954599B (en) 1996-01-26
IL114049A (en) 2000-08-31
IL114049A0 (en) 1995-10-31
AU2821895A (en) 1996-01-04
EP0764032B1 (de) 2002-04-10
WO1995033489A1 (en) 1995-12-14
CA2191773C (en) 2004-08-10
IL122358A (en) 2001-01-28
US6258830B1 (en) 2001-07-10
PT1147778E (pt) 2006-12-29
EP1147778A1 (de) 2001-10-24
CA2191773A1 (en) 1995-12-14
TW379143B (en) 2000-01-11
DE69535184D1 (de) 2006-09-28
DE69535184T2 (de) 2007-08-23
ES2173958T3 (es) 2002-11-01
ES2269296T3 (es) 2007-04-01
US5914334A (en) 1999-06-22
DE69526344T2 (de) 2002-11-07
DK1147778T3 (da) 2006-12-18
EP0764032A1 (de) 1997-03-26

Similar Documents

Publication Publication Date Title
DE69535184D1 (de) Stabile Gelzusammensetzung zur topischen Behandlung von Hautkrankheiten
ATE214933T1 (de) Dermatologische zusammensetzungen, welche benzylneroxid und ein mittel zur verminderung von hautreizungen enthalten
FR2782269B1 (fr) Composition cosmetique et/ou dermatologique contenant de l'acide salicylique ou un derive d'acide salicylique et son utilisation
PT772600E (pt) Compostos de imidazolilo substituido nas posicoes 1 e 2 para o tratamento da inflamacao
DE69634430D1 (de) Formulierung fur die wundheilung mit menschlichem plasma fibronektin
ES2164434T3 (es) Tratamiento topico de psoriasis que utiliza anticuerpos neutralizantes de il-8.
DE69932939D1 (de) Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
ATE167393T1 (de) Verfahren zur hautpflege und mittel
ATE249819T1 (de) Präparate zur äusserlichen anwendung zur behandlung von dermatosen
FI862609A0 (fi) Akne motverkande produkt.
ATE160561T1 (de) L-carnitin-salz, dieses enthaltende kosmetische und pharmazeutische zusammensetzungen zur behandlung von dermatosen
NZ506681A (en) Disinfecting composition
BR9802796A (pt) Utilização de uma dispersão aquosa de glóbulos oleosos e processo de tratamento cosmético.
CA2322878A1 (en) Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
DE3853884D1 (de) Kombination aus minoxidil und einer antiinflammatorischen substanz zur behandlung der alopezie.
EP0801945A3 (de) Verwendung von Glucosiden von Ferulasäure als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen
DK0700897T3 (da) L-carnitinsalt og kosmetiske og farmaceutiske præparater indeholdende samme til behandling af hudsygdomme
DE69919597D1 (de) Topische formulierungen, die hautpenetrations-mittel enthalten, und ihre verwendung
BR9504089A (pt) Agente para o tratamento ou cuidado de pele irritada ou inflamada e aplicação
ATE86611T1 (de) Topische vorstufen von arzneimitteln zur behandlung von akne und hautkrankheiten.
BR9505116A (pt) Aplicaçao de ácido poliaspártico como agente de curtimento
BR9709989A (pt) Processos para tratamento de uma doenca de planta, para preparacão de uma substância ou composicão para tratamento de doenca de planta e para fertilizacão de uma planta, para fertilizacao de uma planta, substâncias ou composicões para tratamento de uma doenca de planta e para fertilizacão de uma planta, e, uso das mesmas.
RU97107046A (ru) Мазь "аникол" для лечения ран, воспалительных и кожных заболеваний у животных
DE69825322D1 (de) Topische carbamazepin-formulierungen und deren verwendung
DE69831336D1 (de) Tazaroten und uvb-phototherapie zur behandlung von psoriasis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1147778

Country of ref document: EP